EUVIMEDEUVIMED entdecken
Übersichtsarbeit

CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences

Duc-Hiep Bach iD, Thanh Liem Nguyen

Human Gene Therapy · 2026

DOI: 10.1177/10430342261467645 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Human Gene Therapy, 2026. Verfasst von Duc-Hiep Bach und 1 weiteren Autor:innen. Beteiligte Einrichtung: Vinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, VinUniversity, Hanoi, Vietnam. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Receptors, Chimeric Antigen, T-Lymphocytes. Die Arbeit nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR) T-cell therapy has transformed hematological cancer care, yet variability in efficacy, durability, and safety cannot be explained solely by antigen selection or patient factors. We propose that manufacturing platforms are active biological determinants of outcome. Viral vectors, used in all licensed products, provide stable genomic integration and durable expression but are limited by cost, cargo capacity, and centralized production. Nonviral strategies, including transposons, CRISPR knock-ins, and messenger RNA delivery, enable faster, less-expensive manufacturing with larger payloads, while introducing distinct safety and persistence profiles. This review presents a three-layer mechanistic framework that reframes manufacturing as biology: integration biology determines genomic risk and transgene stability; clonal fitness shapes persistence, dominance, and exhaustion; and epigenomic imprinting, influenced by gene transfer method, cytokines, and culture stress, preconfigures functional trajectories. Clinical observations link platform choice to immune recovery, where prolonged B-cell aplasia and delayed T-cell reconstitution contribute to infection-related nonrelapse mortality, and hematopoietic reserve at apheresis emerges as a practical predictor. Finally, manufacturing is positioned as the key to democratizing cell therapy. Decentralized, nonviral production aligned with regulatory standards may enable equitable access and transition CAR-T therapy from innovation to sustainable global care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptiveReceptors, Chimeric AntigenT-LymphocytesHumansAnimalsGenetic VectorsGene Transfer Techniques

Stichwörter der Autor:innen

CAR-T manufacturing platformsclonal fitnessepigenomic imprintingimmune reconstitutionnonviral gene delivery

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Vinmec Research Institute of Stem Cell and Gene Technology, College of Health Sciences, VinUniversity, Hanoi, Vietnam.

ORCID-Profile: Duc-Hiep Bach

Zitieren

APA

Bach, D. H., & Nguyen, T. L. (2026). CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences. Human Gene Therapy. https://doi.org/10.1177/10430342261467645

Vancouver

Bach DH, Nguyen TL. CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences. Human Gene Therapy. 2026. doi:10.1177/10430342261467645

BibTeX
@article{Bach2026,
  author = {Bach, Duc-Hiep and Nguyen, Thanh Liem},
  title = {CAR-T Cell Therapy: Manufacturing Platforms and Clinical Consequences},
  journal = {Human Gene Therapy},
  year = {2026},
  doi = {10.1177/10430342261467645}
}
Kostenlos starten →